Different perspectives on outcomes in patients with non-ST-elevation myocardial infarction when observed in clinical trials and in real life

Affiliations

Comment

Lars Wallentin. Eur Heart J. 2018.

. 2018 Nov 7;39(42):3821-3824.

doi: 10.1093/eurheartj/ehy610.

¹ Department of Medical Sciences and Uppsala Clinical Research Center, Uppsala Science Park, Uppsala, Sweden.

No abstract available

Figures

Modes and timing of death in 66 252 patients with non-ST-segment elevation acute coronary syndromes enrolled in 14 TIMI trials.
Berg DD, Wiviott SD, Braunwald E, Guo J, Im K, Kashani A, Gibson CM, Cannon CP, Morrow DA, Bhatt DL, Mega JL, O'Donoghue ML, Antman EM, Newby LK, Sabatine MS, Giugliano RP. Berg DD, et al. Eur Heart J. 2018 Nov 7;39(42):3810-3820. doi: 10.1093/eurheartj/ehy556. Eur Heart J. 2018. PMID: 30239711 Free PMC article.

1. Falk E, Shah PK, Fuster V.. Coronary plaque disruption. Circulation 1995;92:657–671. - PubMed
1. Lindahl B, Venge P, Wallentin L.. Relation between troponin T and the risk of subsequent cardiac events in unstable coronary artery disease. The FRISC study group. Circulation 1996;93:1651–1657. - PubMed
1. Risk of myocardial infarction and death during treatment with low dose aspirin and intravenous heparin in men with unstable coronary artery disease. The RISC Group. Lancet 1990;336:827–830. - PubMed
1. Wallentin L. Low-molecular-weight heparin during instability in coronary artery disease, Fragmin during Instability in Coronary Artery Disease (FRISC) study group. Lancet 1996;347:561–568. - PubMed
1. Invasive compared with non-invasive treatment in unstable coronary-artery disease: FRISC II prospective randomised multicentre study. FRagmin and Fast Revascularisation during InStability in Coronary artery disease Investigators. Lancet 1999;354:708–715. - PubMed